These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 32814319

  • 1. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R, Bidlingmaier M, Kreitschmann-Andermahr I, Land C, Partsch CJ, Schwab KO, Sommer H, Backeljauw P, Kanumakala S, Loche S, Zouater H, Strasburger CJ.
    Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319
    [Abstract] [Full Text] [Related]

  • 2. Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies.
    Lundberg E, Kriström B, Zouater H, Deleskog A, Höybye C.
    BMC Endocr Disord; 2020 Apr 29; 20(1):55. PubMed ID: 32349731
    [Abstract] [Full Text] [Related]

  • 3. Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.
    Backeljauw P, Kanumakala S, Loche S, Schwab KO, Pfäffle RW, Höybye C, Lundberg E, Battelino T, Kriström B, Giemza T, Zouater H.
    Horm Res Paediatr; 2021 Apr 29; 94(3-4):133-143. PubMed ID: 34350858
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study.
    Iughetti L, Tornese G, Street ME, Napoli F, Giavoli C, Antoniazzi F, Stagi S, Luongo C, Azzolini S, Ragusa L, Bona G, Zecchino C, Aversa T, Persani L, Guazzarotti L, Zecchi E, Pietropoli A, Zucchini S.
    Ital J Pediatr; 2016 Nov 03; 42(1):93. PubMed ID: 27809913
    [Abstract] [Full Text] [Related]

  • 5. Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data.
    Backeljauw P, Kanumakala S, Loche S, Schwab KO, Miller BS, Levy R, McCormick K, Zouater H, Zabransky M, Campbell K.
    Eur J Pediatr; 2022 Jun 03; 181(6):2367-2378. PubMed ID: 35275291
    [Abstract] [Full Text] [Related]

  • 6. Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study.
    Loche S, Kanumakala S, Backeljauw P, Schwab KO, Lechuga-Sancho AM, Esmael A, Urosevic D, Boldea A, Zabransky M.
    Drug Des Devel Ther; 2024 Jun 03; 18():667-684. PubMed ID: 38454934
    [Abstract] [Full Text] [Related]

  • 7. PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope® (somatropin) treatment in children: update on the United States cohort.
    Backeljauw P, Miller BS, Levy R, McCormick K, Zouater H, Zabransky M, Campbell K.
    J Pediatr Endocrinol Metab; 2021 Apr 27; 34(4):431-440. PubMed ID: 33647196
    [Abstract] [Full Text] [Related]

  • 8. Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults).
    Höybye C, Beck-Peccoz P, Murray RD, Simsek S, Stalla G, Strasburger CJ, Urosevic D, Zouater H, Johannsson G.
    Pituitary; 2021 Aug 27; 24(4):622-629. PubMed ID: 33742320
    [Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.
    Iughetti L, Antoniazzi F, Giavoli C, Bona G, Aversa T, Greggio NA, Guazzarotti L, Minelli R, Perrone L, Persani L, Pozzobon G, Ragusa L, Stagi S, Tornese G, Zecchino C, Gallinari P, Zouater H, Fedeli P, Zucchini S.
    J Endocrinol Invest; 2021 Mar 27; 44(3):493-503. PubMed ID: 32557273
    [Abstract] [Full Text] [Related]

  • 10. Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.
    Schwarz HP, Walczak M, Birkholz-Walerzak D, Szalecki M, Nanu M, Woehling H, Schuck E.
    Adv Ther; 2016 Mar 27; 33(3):423-34. PubMed ID: 26886776
    [Abstract] [Full Text] [Related]

  • 11. Growth hormone treatment in children with Prader-Willi syndrome: safety and effectiveness data from the PATRO Children study.
    Lämmer C, Backeljauw P, Tauber M, Kanumakala S, Loche S, Otfried Schwab K, Pfäffle R, Höybye C, Lundberg E, Dahlgren J, Ek AE, Battelino T, Kriström B, Esmael A, Zabransky M.
    Ther Adv Endocrinol Metab; 2024 Mar 27; 15():20420188241264343. PubMed ID: 39371577
    [Abstract] [Full Text] [Related]

  • 12. No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study.
    Beck-Peccoz P, Höybye C, Murray RD, Simsek S, Zabransky M, Zouater H, Stalla G.
    BMC Endocr Disord; 2019 Dec 11; 19(1):138. PubMed ID: 31829160
    [Abstract] [Full Text] [Related]

  • 13. Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population.
    Arosio M, Arnaldi G, Gasco V, Giavoli C, Puxeddu E, Vettor R, Ambrosio MR, Gallinari P, Zouater H, Fedeli P, Ferone D.
    J Endocrinol Invest; 2021 Feb 11; 44(2):327-337. PubMed ID: 32507990
    [Abstract] [Full Text] [Related]

  • 14. Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study.
    López-Siguero J, Borrás Pérez MV, Balser S, Khan-Boluki J.
    Adv Ther; 2011 Oct 11; 28(10):879-93. PubMed ID: 21948492
    [Abstract] [Full Text] [Related]

  • 15. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) in children requiring growth hormone treatment.
    Pfäffle R, Schwab KO, Marginean O, Walczak M, Szalecki M, Schuck E, Zabransky M, Zucchini S.
    Ther Adv Endocrinol Metab; 2013 Feb 11; 4(1):3-11. PubMed ID: 23515245
    [Abstract] [Full Text] [Related]

  • 16. Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data.
    López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M.
    Drug Des Devel Ther; 2017 Feb 11; 11():1489-1495. PubMed ID: 28553079
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and Overall Safety of NutropinAq® for Growth Hormone Deficiency and Other Paediatric Growth Hormone Disorders: Completion of the International Cooperative Growth Study, NutropinAq® European Registry (iNCGS).
    Coutant R, Bosch Muñoz J, Dumitrescu CP, Schnabel D, Sert C, Perrot V, Dattani M.
    Front Endocrinol (Lausanne); 2021 Feb 11; 12():676083. PubMed ID: 34113318
    [Abstract] [Full Text] [Related]

  • 18. Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System.
    Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, Muenzberg M, Rapaport R.
    Biol Ther; 2014 Dec 11; 4(1-2):27-39. PubMed ID: 25096555
    [Abstract] [Full Text] [Related]

  • 19. A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial.
    Borrás Pérez V, López-Siguero JP, Martínez G, Corripio R, Fernández JM, Labarta JI, Ferrer M, Cabrinety N, Prieto P, Ramón-Krauel M, Bosch J, Espino R, Palla Garcia M, Rebollo FJ.
    Adv Ther; 2015 Feb 11; 32(2):148-56. PubMed ID: 25667132
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study.
    Ferone D, Profka E, Gasco V, Ambrosio MR, Colao A, Di Somma C, Puxeddu E, Arnaldi G, Pagano C, Zecchi E, Pietropoli A, Beck-Peccoz P.
    J Endocrinol Invest; 2017 Jun 11; 40(6):669-678. PubMed ID: 28161880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.